One of the primary causes of attenuated or loss of efficacy of cancer chemotherapy is the
emergence of multidrug resistance (MDR). Numerous studies have been published …

Resistance to chemotherapy remains one of the most significant obstacles to successful
cancer treatment. While inhibiting drug efflux mediated by ATP-binding cassette (ABC) …

Overexpression of ATP-binding cassette (ABC) transporters is one of the most important
mechanisms responsible for the development of multidrug resistance (MDR). Selonsertib, a …

The overexpression of the human ATP-binding cassette (ABC) transporters in cancer cells is
a common mechanism involved in developing multidrug resistance (MDR). Unfortunately …

Abstract Multidrug resistance protein 7 (MRP7), also known as ATP-binding cassette (ABC)
transporter subfamily C10 (ABCC10), is an ABC transporter that was first identified in 2001 …

Multidrug resistance (MDR) is a serious obstacle encountered in cancer treatment, in which
the overexpression of P-glycoprotein (P-gp) plays an important role. Here, a novel α …

Tyrosine kinase inhibitors (TKIs) are being increasingly used to treat various malignancies.
Although they were designed to target aberrant tyrosine kinases, they are also intimately …

Overexpression of ATP-binding cassette (ABC) transporters is one of the most important
mechanisms responsible for multi-drug resistance (MDR). VS-4718, a tyrosine kinase …

Background: Dual-targeting in cancer treatment by a single drug is an unconventional
approach in relation to drug combinations. The rationale for the development of …

Abstract Ulixertinib (BVD-523) is a highly potent, selective, and reversible ERK1/2 inhibitor
and is currently in clinical development for the treatment of advanced solid tumors. In this …